Bambuterol

Identification

Summary

Bambuterol is a long acting beta2-adrenoceptor agonist for the management of lung diseases associated with bronchospasm.

Generic Name
Bambuterol
DrugBank Accession Number
DB01408
Background

Bambuterol is a long acting beta-adrenoceptor agonist used in the treatment of asthma. It is a prodrug of terbutaline.

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 367.44
Monoisotopic: 367.210721053
Chemical Formula
C18H29N3O5
Synonyms
  • (±)-5-(2-(tert-butylamino)-1-hydroxyethyl)-m-phenylene bis(dimethylcarbamate)
  • Bambuterol
  • bambutérol
  • Bambuterolum

Pharmacology

Indication

For the prevention and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Treatment ofBronchial asthma••••••••••••••••••
Treatment ofBronchospasm••••••••••••••••••
Treatment ofChronic bronchitis••••••••••••••••••
Treatment ofEmphysema••••••••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Bambuterol is a long acting beta2-adrenoceptor agonist used in the treatment of asthma. It is a prodrug of terbutaline. Bambuterol causes smooth muscle relaxation, resulting in dilation of bronchial passages.

Mechanism of action

The pharmacologic effects of bambuterol are at least in part attributable to stimulation through beta-adrenergic receptors (beta 2 receptors) of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic AMP. Increased cyclic AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.

TargetActionsOrganism
ABeta-2 adrenergic receptor
agonist
Humans
UCholinesterase
inhibitor
Humans
Absorption

Bioavailability is 20% following oral administration.

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Hepatic, extensive. Further metabolized to terbutaline by plasma cholinesterase.

Hover over products below to view reaction partners

Route of elimination

Not Available

Half-life

13 hours for bambuterol and 21 hours for the primary active metabolite terbutaline.

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcebutololThe therapeutic efficacy of Bambuterol can be decreased when used in combination with Acebutolol.
AceclofenacThe risk or severity of hypertension can be increased when Bambuterol is combined with Aceclofenac.
AcemetacinThe risk or severity of hypertension can be increased when Bambuterol is combined with Acemetacin.
AcetylcholineThe risk or severity of adverse effects can be increased when Bambuterol is combined with Acetylcholine.
Acetylsalicylic acidThe risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Bambuterol.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Bambuterol hydrochloride786Q84QZ3F81732-46-9LBARATORRVNNQM-UHFFFAOYSA-N
Active Moieties
NameKindUNIICASInChI Key
TerbutalineprodrugN8ONU3L3PG23031-25-6XWTYSIMOBUGWOL-UHFFFAOYSA-N
International/Other Brands
Bambec / Oxeol
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
BAMBEC TABLET 10 mgTablet10 mgOralAstrazeneca Ab1997-03-06Not applicableSingapore flag

Categories

ATC Codes
R03CC12 — Bambuterol
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as phenoxy compounds. These are aromatic compounds contaning a phenoxy group.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenoxy compounds
Direct Parent
Phenoxy compounds
Alternative Parents
Aralkylamines / Carbamate esters / Secondary alcohols / Organic carbonic acids and derivatives / 1,2-aminoalcohols / Dialkylamines / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
show 1 more
Substituents
1,2-aminoalcohol / Alcohol / Amine / Aralkylamine / Aromatic alcohol / Aromatic homomonocyclic compound / Carbamic acid ester / Carbonic acid derivative / Carbonyl group / Hydrocarbon derivative
show 10 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
carbamate ester, phenylethanolamines (CHEBI:553827)
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
Y1850G1OVC
CAS number
81732-65-2
InChI Key
ANZXOIAKUNOVQU-UHFFFAOYSA-N
InChI
InChI=1S/C18H29N3O5/c1-18(2,3)19-11-15(22)12-8-13(25-16(23)20(4)5)10-14(9-12)26-17(24)21(6)7/h8-10,15,19,22H,11H2,1-7H3
IUPAC Name
3-[2-(tert-butylamino)-1-hydroxyethyl]-5-[(dimethylcarbamoyl)oxy]phenyl N,N-dimethylcarbamate
SMILES
CN(C)C(=O)OC1=CC(=CC(OC(=O)N(C)C)=C1)C(O)CNC(C)(C)C

References

Synthesis Reference

Peter Jaksch, "Method of preparing an intermediate for the manufacture of bambuterol." U.S. Patent US5200551, issued May, 1986.

US5200551
General References
Not Available
Human Metabolome Database
HMDB0015478
KEGG Drug
D07377
PubChem Compound
54766
PubChem Substance
46505785
ChemSpider
49466
BindingDB
50235800
RxNav
18751
ChEBI
553827
ChEMBL
CHEMBL521589
Therapeutic Targets Database
DAP000250
PharmGKB
PA164743113
Wikipedia
Bambuterol

Clinical Trials

Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package
PhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additional columns
4CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1somestatusstop reasonjust information to hide
4Unknown StatusTreatmentCough Variant Asthma / Eosinophilic Bronchitis1somestatusstop reasonjust information to hide
1CompletedTreatmentHigh Altitude Pulmonary Hypertension1somestatusstop reasonjust information to hide

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
TabletOral
TabletOral10 mg/1
TabletOral10.000 mg
TabletOral20 mg
TabletOral10 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.469 mg/mLALOGPS
logP1.69ALOGPS
logP1.4Chemaxon
logS-2.9ALOGPS
pKa (Strongest Acidic)13.91Chemaxon
pKa (Strongest Basic)9.52Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count4Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area91.34 Å2Chemaxon
Rotatable Bond Count8Chemaxon
Refractivity98.28 m3·mol-1Chemaxon
Polarizability40.77 Å3Chemaxon
Number of Rings1Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.8638
Blood Brain Barrier-0.761
Caco-2 permeable-0.6746
P-glycoprotein substrateSubstrate0.7076
P-glycoprotein inhibitor INon-inhibitor0.8708
P-glycoprotein inhibitor IINon-inhibitor0.8921
Renal organic cation transporterNon-inhibitor0.9451
CYP450 2C9 substrateNon-substrate0.7745
CYP450 2D6 substrateNon-substrate0.8167
CYP450 3A4 substrateNon-substrate0.5157
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9155
CYP450 2D6 inhibitorInhibitor0.8689
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.927
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9738
Ames testNon AMES toxic0.7909
CarcinogenicityNon-carcinogens0.762
BiodegradationNot ready biodegradable0.9963
Rat acute toxicity2.5730 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9727
hERG inhibition (predictor II)Non-inhibitor0.937
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0089-9051000000-22fa835c1eff90e954e6
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0006-1290000000-f8e18061114ec89ffeda
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0006-2091000000-e26464000c9c569da85c
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-014i-0009000000-d64caf62def7e368fe76
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0006-0090000000-4b6d8dbaef2a0c473d2f
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-00di-0091000000-c54a863e7100305e26cf
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0ab9-9060000000-6c88eb12b785b25449f7
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0pia-0090000000-567c4d0c126bd8d2cdd9
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-204.173351
predicted
DarkChem Lite v0.1.0
[M-H]-186.4136
predicted
DeepCCS 1.0 (2019)
[M+H]+204.304451
predicted
DarkChem Lite v0.1.0
[M+H]+188.8252
predicted
DeepCCS 1.0 (2019)
[M+Na]+204.300451
predicted
DarkChem Lite v0.1.0
[M+Na]+195.98637
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Agonist
General Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine
Specific Function
adenylate cyclase binding
Gene Name
ADRB2
Uniprot ID
P07550
Uniprot Name
Beta-2 adrenergic receptor
Molecular Weight
46458.32 Da
References
  1. Rosberg B, Schroder C, Nyberg L, Rosenborg J, Wiren JE: Bambuterol and terbutaline in human cerebrospinal fluid and plasma. Eur J Clin Pharmacol. 1993;45(2):147-50. [Article]
  2. Svensson LA: Bambuterol, a bronchodilator prodrug with sustained action, enhances delivery of active drug to the lung. Agents Actions Suppl. 1988;23:271-6. [Article]
  3. Waldeck B: Beta-adrenoceptor agonists and asthma--100 years of development. Eur J Pharmacol. 2002 Jun 7;445(1-2):1-12. [Article]
  4. Coleman RA, Johnson M, Nials AT, Vardey CJ: Exosites: their current status, and their relevance to the duration of action of long-acting beta 2-adrenoceptor agonists. Trends Pharmacol Sci. 1996 Sep;17(9):324-30. [Article]
  5. Zhang D, Cheng M, Hyun MH, Xiong Z, Pan L, Li F: Enantiomeric separation of beta2-agonists on macrocyclic antibiotic chiral stationary phases in high performance liquid chromatography. Pharmazie. 2007 Nov;62(11):836-40. [Article]
  6. Chou YL, Wu CC, Wang HW: Effects of bambuterol and terbutaline on isolated rat's tracheal smooth muscle. Eur Arch Otorhinolaryngol. 2010 Aug;267(8):1305-11. doi: 10.1007/s00405-009-1173-7. Epub 2009 Dec 12. [Article]
  7. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
  8. Zhou Y, Zhang Y, Zhao D, Yu X, Shen X, Zhou Y, Wang S, Qiu Y, Chen Y, Zhu F: TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters
Specific Function
acetylcholinesterase activity
Gene Name
BCHE
Uniprot ID
P06276
Uniprot Name
Cholinesterase
Molecular Weight
68417.575 Da
References
  1. Li S, Li AJ, Travers J, Xu T, Sakamuru S, Klumpp-Thomas C, Huang R, Xia M: Identification of Compounds for Butyrylcholinesterase Inhibition. SLAS Discov. 2021 Dec;26(10):1355-1364. doi: 10.1177/24725552211030897. Epub 2021 Jul 16. [Article]
  2. Tunek A, Hjertberg E, Mogensen JV: Interactions of bambuterol with human serum cholinesterase of the genotypes EuEu (normal), EaEa (atypical) and EuEa. Biochem Pharmacol. 1991 Feb 1;41(3):345-8. doi: 10.1016/0006-2952(91)90530-i. [Article]
  3. Wu J, Tian Y, Wang S, Pistolozzi M, Jin Y, Zhou T, Roy G, Xu L, Tan W: Design, synthesis and biological evaluation of bambuterol analogues as novel inhibitors of butyrylcholinesterase. Eur J Med Chem. 2017 Jan 27;126:61-71. doi: 10.1016/j.ejmech.2016.08.061. Epub 2016 Aug 26. [Article]
  4. Feldman S, Karalliedde L: Drug interactions with neuromuscular blockers. Drug Saf. 1996 Oct;15(4):261-73. doi: 10.2165/00002018-199615040-00004. [Article]
  5. Ostergaard D, Rasmussen SN, Viby-Mogensen J, Pedersen NA, Boysen R: The influence of drug-induced low plasma cholinesterase activity on the pharmacokinetics and pharmacodynamics of mivacurium. Anesthesiology. 2000 Jun;92(6):1581-7. doi: 10.1097/00000542-200006000-00014. [Article]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters
Specific Function
acetylcholinesterase activity
Gene Name
BCHE
Uniprot ID
P06276
Uniprot Name
Cholinesterase
Molecular Weight
68417.575 Da
References
  1. Gazic I, Bosak A, Sinko G, Vinkovic V, Kovarik Z: Preparative HPLC separation of bambuterol enantiomers and stereoselective inhibition of human cholinesterases. Anal Bioanal Chem. 2006 Aug;385(8):1513-9. Epub 2006 Jul 25. [Article]
  2. Bosak A, Gazic Smilovic I, Sinko G, Vinkovic V, Kovarik Z: Metaproterenol, isoproterenol, and their bisdimethylcarbamate derivatives as human cholinesterase inhibitors. J Med Chem. 2012 Aug 9;55(15):6716-23. doi: 10.1021/jm300289k. Epub 2012 Jul 27. [Article]
  3. Tunek A, Hjertberg E, Mogensen JV: Interactions of bambuterol with human serum cholinesterase of the genotypes EuEu (normal), EaEa (atypical) and EuEa. Biochem Pharmacol. 1991 Feb 1;41(3):345-8. doi: 10.1016/0006-2952(91)90530-i. [Article]
  4. Chen XY, Xu HY, Zhong DF, Yang HY, Zhang YF: [Determination of bambuterol in human plasma by liquid chromatography-electrospray tandem mass spectrometry: application to pharmacokinetic study]. Yao Xue Xue Bao. 2001 Oct;36(10):762-5. [Article]
  5. Tunek A, Levin E, Svensson LA: Hydrolysis of 3H-bambuterol, a carbamate prodrug of terbutaline, in blood from humans and laboratory animals in vitro. Biochem Pharmacol. 1988 Oct 15;37(20):3867-76. doi: 10.1016/0006-2952(88)90068-8. [Article]
  6. Nyberg L, Rosenborg J, Weibull E, Jonsson S, Kennedy BM, Nilsson M: Pharmacokinetics of bambuterol in healthy subjects. Br J Clin Pharmacol. 1998 May;45(5):471-8. doi: 10.1046/j.1365-2125.1998.00695.x. [Article]
  7. Staun P, Lennmarken C, Eriksson LI, Wiren JE: The influence of 10 mg and 20 mg of bambuterol on the duration of succinylcholine-induced neuromuscular blockade. Acta Anaesthesiol Scand. 1990 Aug;34(6):498-500. [Article]

Drug created at July 17, 2007 12:34 / Updated at November 03, 2024 03:45